Hanmi Science stock faces a new shareholder control test

Published on 10/07/2026 at 04:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanmi Science stock faces a KRW 60 billion shareholder dispute after an October 1 court ruling. Q2 revenue reached KRW 368 billion, up 8.7 percent year over year.

Hanmi Science, KR7008930000, Illustration mit AI erstellt.

Hanmi Science (ISIN KR7008930000) was trading at KRW 57,300 on the KOSPI at 11:30 a.m. KST on October 7, 2026, down 0.52 percent from the prior close. The company remains tied to a shareholder-control dispute after a Seoul court dismissed a KRW 60 billion penalty claim on October 1.

Court ruling reshapes shareholder conflict

According to Asiae, the Seoul Central District Court dismissed claims brought by Song Young-sook, Lim Joo-hyun and Killington against Shin Dong-kuk. The plaintiffs had sought more than KRW 60 billion over a shareholder agreement linked to a senior-care investment decision.

The October 1 judgment was a first-instance ruling. BizHankook reported that the court found no evidence that the alliance had reached a definitive agreement to make the investment, leaving the shareholder conflict as a central governance variable for Hanmi Science.

October 26 brings a major ownership date

A separate transaction adds a dated ownership checkpoint. According to CHOSUNBIZ, Song Young-sook agreed on September 22 to sell 1.7 million Hanmi Science shares to WilloN at KRW 50,600 per share, implying a transaction value of KRW 86.02 billion. The closing date is October 26, 2026.

The transaction would reduce Song's direct stake from 3.84 percent to below 1 percent, while the article said the total holding of the broader largest-shareholder side would remain unchanged. That distinction matters because the transfer changes the internal balance of ownership without changing the group's overall position.

Q2 profit rises faster than revenue

Hanmi Science reported Q2 2026 revenue of KRW 368 billion, up 8.7 percent year over year, and operating profit of KRW 59.1 billion, according to ATS View. The operating margin was 16.1 percent, compared with 9.5 percent in Q1 2026, while Q1 revenue was KRW 354 billion.

The earnings sequence gives the governance story a financial counterweight: Q2 operating profit of KRW 59.1 billion stood above Q1's KRW 33.6 billion, while revenue increased by KRW 14 billion quarter over quarter. ATS View identifies Hanmi Science as a KOSPI-listed holding company with businesses spanning healthcare, food, medical devices and digital services.

Stock trades below yearly high

Hanmi Science was trading at KRW 57,300 on the Korea Exchange KOSPI on October 7, 2026, with a market capitalization of KRW 3.9 trillion. Its 52-week range was KRW 25,600 to KRW 61,000, placing the price below the yearly high while the shareholder timetable approaches its October 26 closing date.